414 related articles for article (PubMed ID: 31028836)
1. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.
Mahalingaiah PK; Ciurlionis R; Durbin KR; Yeager RL; Philip BK; Bawa B; Mantena SR; Enright BP; Liguori MJ; Van Vleet TR
Pharmacol Ther; 2019 Aug; 200():110-125. PubMed ID: 31028836
[TBL] [Abstract][Full Text] [Related]
2. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
6. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
7. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.
Simmons JK; Burke PJ; Cochran JH; Pittman PG; Lyon RP
Toxicol Appl Pharmacol; 2020 Apr; 392():114932. PubMed ID: 32109510
[TBL] [Abstract][Full Text] [Related]
8. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.
Hammood M; Craig AW; Leyton JV
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358100
[TBL] [Abstract][Full Text] [Related]
9. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
10. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
11. In vivo safety testing of Antibody Drug Conjugates.
Pretto F; FitzGerald RE
Regul Toxicol Pharmacol; 2021 Jun; 122():104890. PubMed ID: 33587934
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates: A Comprehensive Review.
Khongorzul P; Ling CJ; Khan FU; Ihsan AU; Zhang J
Mol Cancer Res; 2020 Jan; 18(1):3-19. PubMed ID: 31659006
[TBL] [Abstract][Full Text] [Related]
13. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
14. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
15. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
17. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
Leal AD; Krishnamurthy A; Head L; Messersmith WA
Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
[TBL] [Abstract][Full Text] [Related]
20. Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies.
Kulkarni C; Finley JE; Bessire AJ; Zhong X; Musto S; Graziani EI
Bioconjug Chem; 2017 Apr; 28(4):1041-1047. PubMed ID: 28191936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
